Ceres, a producer of genetically-engineered bioenergy feedstocks, has seen its price fall by 92% since its IPO due to a lack of global demand for lignocellulosic feedstocks and consecutive poor growing seasons in Brazil. The most recent hit to its share price came after the company reported highly variable sweet sorghum trial yields in its FQ3 2013 earnings report. While investors now appear to be concerned about the company's risk of default, it has enough cash to last it through another round of consumer trials. The stock is a highly speculative play on the results of these future trials.
Ceres (NASDAQ:CERE), a producer of genetically-engineered bioenergy feedstocks, has seen its share price fall by 64% in...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|